Bristol-Myers Squibb Hits Lowest Level In 2 Years After Mixed Q4 Report

Bristol-Myers Squibb Co BMY shares are trading lower by $0.45 at $49.10 in Thursday's session.

Investors are exiting the issue after a mixed Q4 report that revealed an EPS miss of $0.04 along with a slight revenue beat. The company affirmed FY2017 outlook at the $2.70-$2.90 range versus estimates of $2.86.

The issue, which was under severe selling pressure last week as a result of the announcement that the company will not seek faster approval for its lung cancer drug, has now breached its lows from October.

After a lower open, it continued in that direction before bottoming at $47.81 and staging a rebound. That marks the lowest level for this issue since October 2014, when it bottomed at $47.64.

Since making that low, it has rebounded to make a new high for the session at $49.42, which is just shy of Wednesday's high of $49.57.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!